14results about "Bone morphogenetic factor" patented technology

To provide a composition that significantly improves bone healing and accelerates tissue regrowth.SOLUTION: The present invention provides a chimeric polypeptide that comprises (i) one or more β-tricalcium phosphate (β-TCP)-binding sequence(s), wherein at least one of the one or more β-TCP-binding sequence(s) is selected from the group consisting of specific sequences and (ii) a mammalian growth factor. The present invention also provides a composition containing the chimeric polypeptide.SELECTED DRAWING: Figure 1A

This invention relates to crystals of the human Gremlin-1 protein, and the human Gremlin-1 protein in complex with an inhibitory antibody. The invention also relates to the structure of human Gremlin-1 (on its own, or in complex with the antibody) and uses of these structures in screening for agents which modulate Gremlin-1 activity. The invention further provides antibodies which bind an allosteric inhibitory site on Gremlin-1, together with pharmaceutical compositions and medical uses of such antibodies and agents identified by the screening methods.

A polypeptide or a modifier thereof having an effect of promoting bone formation; can be used for preventing and / or treating bone diseases.

To provide human colonic organoids in vitro, usable for determining the efficacy and / or toxicity of potential therapeutics for a disease selected from the group consisting of colitis, colon cancer, polyposis syndrome and / or irritable bowel syndrome.SOLUTION: The disclosure provides a human colonic organoid (HCO), where the human colonic organoid comprises epithelium and mesenchyme and expresses SATB2, MUC2 and / or MUC5B.SELECTED DRAWING: Figure 1A

Methods are provided for delaying onset or progression of kidney damage, or treating kidney disease, in a subject who has type 1 diabetes or type 2 diabetes or glomerular disease. The methods comprise administering to a subject with type 1 or type 2 diabetes or glomerular disease an effective amount of an agent capable of inhibiting NBL1 activity, and in particular, capable of inhibiting NBL1-mediated toxicity of human podocytes. In some embodiments, the agent is an antibody capable of binding to human NBL1.

The present invention relates to mRNA drugs and their use in the treatment of pulmonary arterial hypertension. In particular, the present invention relates to polynucleotides encoding a peptide comprising a BMP9 active molecule and / or an ACTRIIA ligand trap, lipid nanoparticles comprising said polynucleotides and their therapeutic use.

The present invention relates to a biocompatible matrix material embedded with a quantity of yeast-generated extracellular vesicles (yEVs) configured for the in-situ delivery of one or more therapeutic polynucleotides contained within the yEV, preferably to a diseased or injured tissue or organ.

Methods and materials for making and using extracellular vesicles (EVs) engineered to include BMP2 or BMP2 in combination with BMP7, and cells that can be used to generate such EVs, are provided herein. For example, methods and materials for generating EVs that include BMP2 or BMP2 and BMP7, and methods and materials for using such EVs to induce bone formation, are provided. Methods and materials for making and using minicircle DNAs (mcDNAs) to overexpress BMP2 or BMP2 and BMP7 also are provided herein. For example, methods and materials for generating mcDNAs that encode BMP2 or BMP2 and BMP7, and methods and materials for using such mcDNAs to induce bone formation, are provided.

The application provides a method for efficiently expressing and producing BMP-2 in Escherichia coli. The synergistic effect of the host cell, the BMP-2 fusion protein and the high-density fermentation and induction strategy optimized in the application promotes the high-level expression of the target protein in a soluble and active form, so that the BMP-2 fusion protein accounts for more than 30% of the total soluble protein, the volume yield of the fusion protein in the fermentation liquor reaches an amazing yield of 26 g / L, and the fusion protein has activity after purification. The application simplifies the downstream purification process, reduces the production cost, and fundamentally overcomes the key bottleneck of inclusion body formation existing in the traditional method.

Provided is a novel use for a stem cell culture supernatant. Provided is a composition that contains a stem cell culture supernatant and that is for use in medical or cosmetic applications for a subject.

The application provides an antigen epitope polypeptide and a paralichthys dentatus BMP2 protein specific antibody prepared by the antigen epitope, designs an antigen epitope through bioinformatics analysis, adopts a segmented recombination expression strategy to obtain BMP2-N and BMP2-C recombination proteins in view of the low expression efficiency of full-length BMP2 protein in a prokaryotic system, and uses the recombination proteins as immunogens to prepare polyclonal antibodies. It is verified through immunoblotting and immunofluorescence that the prepared antibodies can specifically recognize the paralichthys dentatus BMP2 protein, have high affinity and good reaction activity, and effectively avoid the problems of false negative or low signal caused by insufficient cross reactivity of the antibodies. On this basis, a BMP2 immunological detection kit is constructed, precise positioning and expression analysis of the BMP2 protein in mucous membrane tissues such as skin, gill and intestinal tract of the paralichthys dentatus can be realized. The antibody and the kit provide a reliable tool for studying the role of BMP2 in fish mucosal immunity, and have important scientific research value and application prospect.